Skip to content

A study on the effectiveness and safety of a new herbal composition (JOFP-002) for managing metabolic syndrome in adults.

A Randomized, Double Blind, Placebo controlled, Parallel Group Clinical Study to evaluate Efficacy and Safety of a Novel herbal composition JOFP-002 in subject with metabolic syndrome. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/099581
Enrollment
60
Registered
2025-12-22
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E782- Mixed hyperlipidemia

Interventions

Intervention1: JOFP-002: JOFP-002 is a standardized 500 mg herbal capsule developed to support metabolic health through a synergistic blend of Cinnamon and Ginger extracts. It is to be taken twice dai

Sponsors

Jeeva Organic Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Male or female subjects between 18 to 65 years of age Ability to understand the risks/benefits of the protocol Female subjects of childbearing potential must be using a medically acceptable form of birth control. Female subjects of non-childbearing potential must be amenorrheic for at least 1 years or had a hysterectomy and/or bilateral oophorectomy Confirmed diagnosis of metabolic syndrome as per ATP-III guidelines. This includes the presence of at least 3 or more of the following 5 factors: (As per modified NCEP ATP III guidelines-specific for South Asia) Including Abdominal waist circumference greater than 90 (males), greater than 80 cm (females) and Increased blood pressure (greater than or equal to 130 per 85 mm Hg) Serum triglycerides greater than or equal to 150 mg per dL Serum HDL cholesterol less than 40 mg per dL (males), less than 50 mg per dL (females) Elevated fasting blood glucose greater than or equal to 100 mg per dL Subjects agree to maintain the activity dairy If Former smoker (previously smoked greater than or equal to 10 cigarettes per day for at least 1 year, cessation for at least 6 months Willing to give written informed consent and willing to comply with trial protocol

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Mean Change from baseline to end of the study in Serum triglycerides Fasting blood glucose Timepoint: Day -7, Day 28, Day 56, Day 84

Secondary

MeasureTime frame
Change from baseline to end of the study in Serum LDL Total Cholesterol Serum HDL Blood Pressure Abdominal waist circumference Change in Body weight Change in Glycosylated haemoglobin (HbA1c) Timepoint: Day -7, Day 28, Day 56, Day 84

Countries

India

Contacts

Public ContactDr P Akash Kumar

Chennai Meenakshi Multispeciality Hospital

drakashkumar93@gmail.com9944066192

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026